Clinical Trials Browser

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

Neoplasm Metastasis, Triple Negative Breast Neoplasms

Carcinoma, Non-Small-Cell Lung

Small Cell Lung Carcinoma

Small Cell Lung Carcinoma

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Small Cell Lung Carcinoma

Lung Neoplasms, Neutropenia, Small Cell Lung Carcinoma

Carcinoma, Non-Small-Cell Lung

Triple Negative Breast Neoplasms

Triple Negative Breast Neoplasms

Head and Neck Neoplasms

Squamous Cell Carcinoma of Head and Neck

Sarcoma, Ewing

Myelosuppression

Esophageal Neoplasms

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

Small Cell Lung Carcinoma

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Endometrial Neoplasms

Osteosarcoma

Breast Neoplasms

Small Cell Lung Carcinoma

Breast Neoplasms

Advanced Squamous Non-Small-Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

Small Cell Lung Carcinoma

Clinical Trials

I-SPY

ToPCourT

the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib

Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy

Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC

PRESERVE3

Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan

Study of Trilaciclib and Lurbinectidin

PROTECT-2

Trilaciclib Combined With Anti-PD-1 Antibody and Chemotherapy in the Treatment of Locally Advanced TNBC

Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer

CCRT，LA-HNSCC

Trilaciclib in Preventing Hematopoietic Suppression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

A Prospective, Randomized, Controlled Clinical Study on the Prevention of Chemotherapy Related Myelosuppression in Patients with Ewing's Sarcoma Using Trilaciclib

Trilaciclib Prevents Myelosuppression With Chemoradiotherapy

Trilaciclib Combined With Concurrent Chemoradiotherapy and Immunotherapy in the Treatment of Esophageal Cancer

PRESERVE 2

Phase 3 Study Evaluating Efficacy, Safety and Pharmacokinetics of Trilaciclib In Small Cell Lung Cancer Patients

A Study of Trilaciclib Combined With Chemotherapy in the Treatment of NSCLC

Myeloprotection With Trilaciclib in Pan-cancer Population

Trilaciclib Combined With Chemotherapy for Perioperative Treatment of Osteosarcoma

SMA-BC-002

Evaluation of TRILACICLIB in Chinese Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC) for Chemotherapy-induced Myelosuppression, Antitumor Effects of Combination Regimens, and Safety in a Real-world Study

The Study of Trilaciclib Combined With Chemotherapy On The Neoadjuvant Therapy of TNBC

Trilaciclib Prior to Chemotherapy Plus Tislelizumab as 1L Treatment for Advanced Squamous Non-Small-Cell Lung Cancer

PRESERVE 4

Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)

Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC)